CANDI

CANDI (cyclodextrin-adjuvant nanoconstructs for dual immunotherapy or Cyclodextrin-Adjuvant Nanoconstructs Double Inhibitor) is a modular, cyclodextrin-based nanoparticle immunotherapy platform developed by researchers at Massachusetts General Hospital and Harvard Medical School. It is designed to target tumor-associated myeloid cells, such as dendritic cells and macrophages, and deliver a combination of small-molecule immunomodulators directly to the tumor microenvironment. The triple-loaded formulation of CANDI (such as CANDI402 or CANDI450) incorporates the TLR7/8 agonist resiquimod (R848), the cIAP inhibitor LCL-161, and the JAK1/2 inhibitor ruxolitinib. This combination synergistically activates the canonical and non-canonical NF-κB pathways while modulating JAK/STAT signaling, leading to robust upregulation of interleukin-12 (IL-12) production, dendritic cell activation, and enhanced T-cell-mediated anti-tumor immunity. CANDI is being investigated for the treatment of glioblastoma and bladder cancer (including non-muscle invasive and metastatic bladder cancer).

Other names

Cyclodextrin-Adjuvant Nanoconstructs Double Inhibitorcyclodextrin-adjuvant nanoconstructs for dual immunotherapy